Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02186223Not ApplicableCompleted

The Angel® Catheter Pivotal Clinical Trial

Role: lead

NCT02917135Unknown

Angel® Catheter Post Market Registry

Role: lead

NCT01847196Not ApplicableTerminated

Angel® Catheter Early Feasibility Clinical Study

Role: lead

NCT01403090Phase 1Completed

Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism

Role: lead

All 4 trials loaded